Zimmer Biomet Holdings to Present at 42nd Annual Deutsche Bank Securities Annual Health Care Conference

Posted On April 20, 2017 By OrthoSpineNews In Recon /  

WARSAW, Ind., April 20, 2017 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that it will be participating in the Deutsche Bank Securities 42nd Annual Health Care Conference at the InterContinental Hotel in Boston, Massachusetts on Wednesday, May 3, 2017.  Zimmer Biomet will present at 11:20 a.m. Eastern Time.

A live webcast of the presentation can be accessed via Zimmer Biomet’s Investor Relations website at http://investor.zimmerbiomet.com.  The webcast will be archived for replay following the conference.

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

SOURCE Zimmer Biomet Holdings, Inc.

Related Links

http://www.zimmerbiomet.com

Read More
knee-bluebox.jpg

FDA Clears Halyard Health’s COOLIEF* for the Management of Osteoarthritis Knee Pain

Posted On April 20, 2017 By OrthoSpineNews In Regulatory /  

LAS VEGAS, April 20, 2017 /PRNewswire/ — American Society of Interventional Pain Physicians Annual Meeting, Booth #407 — Halyard Health (NYSE:  HYH), a medical technology company focused on eliminating pain, speeding recovery and preventing infection, today announced the U.S. Food and Drug Administration (FDA) has cleared for marketing its COOLIEF* Cooled Radiofrequency (Cooled RF) thermal treatment for the relief of chronic moderate to severe knee pain caused by osteoarthritis (OA). The first and only RF treatment to be cleared specifically to relieve OA knee pain, COOLIEF RF is a minimally invasive, thermal radiofrequency pain management system using water-cooled technology to safely deactivate pain-causing sensory nerves.

This new clearance is based on results from a 151-patient prospective, randomized multi-center study comparing COOLIEF Cooled RF to intra-articular steroid injections in patients suffering from knee pain due to osteoarthritis. In 74.1 percent of the cooled RF patient group, pain was reduced by at least 50 percent at six months and maintained in over 65.4 percent of those patients for a full 12 months post procedure1,2. At baseline, 67.1 percent of the cooled RF group and 62.7 percent of the steroid injection group reported symptoms of severe arthritis1,2. Results indicate that six months post-procedure, only 5.2 percent of the cooled RF group reported the same severity level versus 37.3 percent of patients treated with steroid injections, as measured by the Oxford Knee Score1. In addition, the cooled RF patient group’s Oxford Knee Score remained low for 12 months with only 11.5 percent reporting severe symptoms at that point1. The Oxford Knee Score is a validated outcomes instrument designed to assess function and pain associated with the knee1.

“I see many patients who suffer with chronic osteoarthritis knee pain in my practice who are not immediate candidates for knee replacement surgery due to co-morbidities, such as obesity or other chronic health issues,” said Dr. Timothy Davis, founder and medical director, Orthopedic Pain Specialists, and investigator in the recent study. “COOLIEF Cooled RF treatment provides significant pain relief for patients with OA of the knee until they are able to undergo surgery. Until now there have been few options available for my patients.”

According to the Centers for Disease Control and Prevention, OA affects over 30 million adults in the U.S. and is caused by the damage and breakdown of cartilage between bones that can lead to joint pain, swelling and stiffness3. The prevalence of OA is on the rise as both the age and weight of Americans continue to increase4. As cases of OA increase, so do associated economic costs including treatment, adaptation of lives and homes to help patients manage pain caused by the disease, and lost work productivity5.

Surgery can be beneficial in properly selected patients, but due to BMI, age, co-morbidities, invasiveness or lack of necessary support systems, some patients are either not candidates for surgery, or are forced to delay surgery6. Patients suffering from chronic knee pain wait an average of nine years until they are ready or qualify for surgery6.

Prior to surgery, initial treatments for knee pain often include nonsteroidal anti-inflammatory drugs, opioids and steroid injections. Medication provides only short-term relief and comes with serious risks, which include opioid abuse and dependence7. According to the Mayo Clinic, one in four patients prescribed opioid painkillers is at risk to progress to episodic or long-term prescription use8. Healthcare providers are becoming more conservative in the use of opioids to reduce associated complications such as nausea, respiratory depression, and even death9,10,11. Steroid injections can provide relief for months at a time, but may have to be repeated for continued pain relief6.     

“Many OA patients try unsuccessfully for years to treat their chronic knee pain with conservative pain therapies before turning to surgery. This treatment is clinically proven to be significantly more effective in relieving OA knee pain, increasing functionality, and decreasing the need for pain medication for up to a year1,” said Lisa Kudlacz, vice president and general manager, Global Interventional Pain, Halyard Health. “The U.S. consumes an astounding 80 percent of the global opioid supply with only five percent of the population7,12. At Halyard we are committed to helping curb the opioid epidemic by providing solutions that help patients manage pain without the risk of addiction.”

To learn more about COOLIEF, please visit http://www.halyardhealth.com/chronicpain.

About Halyard Health
Halyard Health Inc. (NYSE: HYH) is a medical technology company focused on eliminating pain, speeding recovery and preventing infection for healthcare providers and their patients. Headquartered in Alpharetta, Georgia, Halyard is committed to addressing some of today’s most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery and preventing healthcare-associated infections. Halyard’s business segments – Medical Devices and Surgical and Infection Prevention (S&IP) – develop, manufacture and market clinically superior solutions that improve medical outcomes and business performance in more than 100 countries. For more information, visit www.halyardhealth.com.

*Registered Trademarks or Trademarks of Halyard Health, Inc. or its affiliates.

1 Halyard Health Inc. sponsored study: A Prospective, Multi-Center, Randomized, Clinical Trial Evaluating the Safety and Effectiveness of Using COOLIEF™ Cooled Radiofrequency Probe to Create Lesions of the Genicular Nerves and Comparing Corticosteroid Injection in the Management of Knee Pain. Final results 03Apr2017. Study available upon request from Halyard.
2 Davis T. Cooled RF Ablation Superior to Corticosteroids in Knee Osteoarthritis. Pain Medicine News [Internet]. 2017Feb2; Available from: http://www.painmedicinenews.com/Multimedia/Article/02-17/Cooled-RF-Ablation-Superior-to-Corticosteroids-in-Knee-Osteoarthritis/40262/ses=ogst?enl=true
3Osteoarthritis Fact Sheet [Internet]. CDC.gov. Centers for Disease Control and Prevention; 2017 [cited 2017Apr12]. Available from: https://www.cdc.gov/arthritis/basics/osteoarthritis.htm
4 Bliddal H, Christensen R. The treatment and prevention of knee osteoarthritis: a tool for clinical decision-making. Expert Opinion on Pharmacotherapy. 18 June 2009; 10(11):1793-804.
5 Altman RD. Early Management of Osteoarthritis. Am J Manag Care. 2010;16 (Suppl Management):S41-47.[PubMed]
6 KS&R. Halyard sponsored study: Osteoarthritis Pain Landscape & Patient Journey. 2015. Data on file.
7AAOS – American Academy of Orthopedic Surgeons. Opioid Use, Misuse, and Abuse in Orthopaedic Practice. Information Statement 1045. http://www.aaos.org/uploadedFiles/PreProduction/About/Opinion_Statements/advistmt/1045%20Opioid%20Use,%20Misuse,%20and%20Abuse%20in%20Practice.pdf Published October 2015.
8 Mayo Clinic. “One in four people prescribed opioids progressed to longer-term prescriptions.” ScienceDaily, July 1, 2015. www.sciencedaily.com/releases/2015/07/150701115325.htm
9 Morrison RS, Magaziner J, Gilbert M, Koval KJ, McLaughlin MA, et al. Relationship Between Pain and Opioid Analgesics on the Development of Delirium Following Hip Fracture. Journal of Gerontology. 2003;58A(1):76–81.
10 Sieber FE, Mears S, Lee H, Gottschalk A. Postoperative Opioid Consumption and Its Relationship to Cognitive Function in Older Adults with Hip Fracture. Journal of the American Geriatrics Society. 2011Dec;59(12):2256–62.
11 Riddell M, Ospina M, Holroyd-Leduc JM. Use of Femoral Nerve Blocks to Manage Hip Fracture Pain among Older Adults in the Emergency Department: A Systematic Review. CJEM. 2016Jul;18(4):245–52.
12 American Society of Interventional Pain Physicians. Fact Sheet

SOURCE Halyard Health, Inc.

Related Links

http://www.halyardhealth.com

Read More
depuy-synthes-1.jpg

DePuy Synthes Acquires Tissue Regeneration System’s 3D Printing Technologies to Treat Bone Defects

Posted On April 20, 2017 By OrthoSpineNews In Financial /  

WEST CHESTER, Pa., April 20, 2017 /PRNewswire/ — DePuy Synthes Products, Inc., part of the Johnson & Johnson Family of Companies, has acquired 3D printing technology from Tissue Regeneration Systems, Inc. (TRS). The 3D printing methods developed by TRS will help enable DePuy Synthes to create patient-specific, bioresorbable implants with a unique mineral coating intended to support bone healing in patients with orthopaedic and craniomaxillofacial deformities and injuries. Financial terms of the transaction have not been disclosed.

The acquisition from TRS brings exciting new technology with the potential to truly personalize health care solutions in Trauma, a priority platform for the business, and builds on DePuy Synthes’ leadership in delivering ground-breaking innovation that improves patients’ lives. With more than 50 strategic collaborations, the Johnson & Johnson Family of Companies is harnessing 3D printing technology to develop patient-specific healthcare solutions that can mean increased satisfaction and better clinical outcomes.

“We are systematically investing in building a pipeline of 3D printed products,” said Ciro Römer, Company Group Chairman, DePuy Synthes. “The TRS technology, which will be added to the DePuy Synthes Trauma Platform, is the latest example of how we are working toward developing next-generation technologies that transform healthcare delivery with individualized solutions for patients.”

DePuy Synthes began collaborating with TRS in 2014 through Johnson & Johnson Innovation, which seeks and invests in the best science and builds novel partnerships at all stages of development across the medical device, consumer healthcare and pharmaceutical sectors. Johnson & Johnson Innovation facilitated the collaboration between DePuy Synthes and TRS.

“The acquisition of the TRS technology by DePuy Synthes is testament to our ability to identify and work collaboratively with promising early-stage companies and entrepreneurs to accelerate bringing innovative new products to market,” said Robert G. Urban, PhD, Global Head, Johnson & Johnson Innovation. “We are excited at the potential this technology holds to help improve patient outcomes.”

Founded in 2008, TRS is an early-stage medical device company headquartered in Plymouth, Mich., commercializing skeletal reconstruction and bone regeneration technology based on research performed at the University of Michigan and the University of Wisconsin.

About DePuy Synthes Companies
DePuy Synthes Companies, part of the Johnson & Johnson Family of Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes Companies solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding anticipated product applications and benefits of 3D printing technologies, including technology recent acquired from Tissue Regeneration Systems, Inc. (TRS). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes Products, Inc., Johnson & Johnson Innovation LLC and/or Johnson & Johnson. Among other risks, there can be no assurance that the technologies acquired from TRS will be successfully developed into effective healthcare solutions and result in commercially successful products. Other risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2017, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. DePuy Synthes Products, Inc., Johnson & Johnson Innovation LLC and Johnson & Johnson do not undertake to update any forward-looking statement as a result of new information or future events or developments.

The third party trademarks used herein are the trademarks of their respective owners.

©DePuy Synthes 2017. All rights reserved.

SOURCE DePuy Synthes

Related Links

http://www.depuysynthes.com

Read More
xm_p5135169.jpg.pagespeed.ic_.rXaTias2lg.jpg

Northwell Announces Affiliation Agreement With Acclaimed Orthopedic Institute

Posted On April 20, 2017 By OrthoSpineNews In Extremities, Sports Medicine, Top Stories /  

NEW HYDE PARK, N.Y., April 20, 2017 /PRNewswire-USNewswire/ — Northwell Health has signed a strategic affiliation agreement with the Rothman Institute, one of the nation’s largest, most-prestigious orthopedic practices.

Headquartered in Philadelphia, Pennsylvania, Rothman Institute is known internationally as a preeminent orthopedic and musculoskeletal practice, with more than 25 locations throughout Pennsylvania and New Jersey, including two orthopedic urgent care clinics.  Rothman Institute is recognized for their innovative treatment methods, research, education and technology.

The Northwell Health Orthopaedic Institute will be working with Rothman Institute to develop centers of excellence for orthopedic care in the New York Metropolitan area, including Manhattan.

“We’re excited about the affiliation with the Rothman Institute,” said Nicholas Sgaglione, MD, chair of orthopedics at Northwell Health. “The affiliation will bring together two nimble, forward-thinking organizations that emphasize high-quality care. We also look forward to working with the Rothman Institute to co-brand various marketing initiatives, the ongoing recruitment of top-level physicians, joint research, and tracking and measuring patient outcomes.”

“We look forward to joining the Northwell Health family,” said Alexander R. Vaccaro, MD, PhD, MBA, president of Rothman Institute, Richard H. Rothman Professor and chairman of the Department of Orthopaedics, and professor of neurosurgery at Thomas Jefferson University and Hospitals. “This agreement expands Rothman Institute’s footprint into New York City and the surrounding suburbs. We are looking forward to bringing our excellent musculoskeletal care to Northwell Health’s communities and patients now and for years to come.”

About Northwell Health
Northwell Health is New York State’s largest health care provider and private employer, with 21 hospitals and over 550 outpatient practices. We care for more than two million people annually in the metro New York area and beyond, thanks to philanthropic support from our communities. Our 61,000 employees – 15,000+ nurses and nearly 3,400 physicians, including nearly 2,700 members of Northwell Health Physician Partners – are working to change health care for the better. We’re making breakthroughs in medicine at the Feinstein Institute. We’re training the next generation of medical professionals at the visionary Hofstra Northwell School of Medicine and the School of Graduate Nursing and Physician Assistant Studies. And we offer health insurance through CareConnect. For information on our more than 100 medical specialties, visit Northwell.edu.

About Rothman Institute
Rothman Institute is a private orthopaedic practice dedicated to providing communities with high-quality, compassionate, and affordable musculoskeletal care that is grounded in evidence-based medicine, the results of which will exceed expectations. Rothman Institute orthopaedists treat patients at over 25 locations in the Philadelphia-region, including orthopaedic urgent care clinics in Marlton, NJ and Limerick, PA.

With experts in orthopaedic sub-specialties including spine, hip and knee, foot and ankle, shoulder and elbow, hand and wrist, sports medicine, physical medicine and  rehabilitation, orthopaedic oncology and trauma, Rothman Institute is internationally recognized for excellence in clinical treatment  methods, research, education and technology. Consistently recognized as national and regional “Top Docs,” Rothman Institute is proud to be the first practice serving as official team physicians for all four of the major professional sports teams in one city, the Philadelphia Eagles, Phillies, Flyers and 76ers, as well as over 40 college and high school teams. For more information about Rothman Institute please call 1-800-321-9999 or visit www.RothmanInstitute.com.

SOURCE Northwell Health

Related Links

https://www.northwell.edu

Read More
ambulatorysurgerycenter.jpeg

Ambulatory Services Market is Expected to Reach 2455.2 Billion by 2022 at a CAGR of 4.7%

Posted On April 20, 2017 By OrthoSpineNews In Financial /  

PUNE, India, April 20, 2017 /PRNewswire/ — Market Research Future published a half-cooked research report on Global Ambulatory Services Market. The Global Market for Ambulatory Services is growing continuously and expected to grow at a CAGR of 4.7% from 2014 to 2022

Market Highlights

The Global Ambulatory Services Market has been evaluated as steadily growing market and it is expected that the market will continue to grow similarly in the near future. Ambulatory services provides cost efficient and convenient healthcare facilities to the patient. Appropriate ambulatory care reduce the chances of impatient care or reduces chances of hospitalization. Ambulatory care is also known as outpatient care which provides different healthcare facilities such as consultation, observation, diagnosis, treatment, rehabilitation services. In ambulatory surgery center, patient need not to admit to the hospital and treatment is done outside the hospital premises.

Ambulatory surgery centers segmented on the basis of types which consist Hospital emergency departments (EDs), Primary care offices, Hospital-based outpatient departments (OPDs), physician private practices, Community Health Centers, Ambulatory surgery centers (ASCs), Urgent Care Centers, and Others. Primary care office segment is growing rapidly and it holds largest market share in ambulatory market. Ambulatory surgery center provides many affordable healthcare services such as pain management, orthopedic, ophthalmology, dermatology, gastroenterology, and others. Government initiative to overcome high healthcare cost and provide affordable medical facilities are driving the growth for ambulatory services market. Increasing aging population and chronic diseases are also major factors which leading the growth for the market. Global Ambulatory Services Market is expected to reach USD 2455.2 billion by 2022 at a CAGR of 4.7%.

North America is the largest market for Ambulatory Services and expected to grow significant rate during the forecast period. Europe is the second largest market for Ambulatory Services and expected to grow steadily during forecasting period. Due to improving healthcare infrastructure and government initiative to provide affordable healthcare facilities in Asia-Pacific region, the market for ambulatory services is expected to grow significantly during the forecast period.

Request a Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/2491

Global Ambulatory Services Market Players:

  • AmSurg Corp. (US),
  • Surgical Care Affiliates (US),
  • Surgery Partners (US),
  • SurgCenter (US),
  • Symbion Inc. (US),
  • Hospital Corporation of America (HCA)
  • Holding (US),
  • Healthway Medical Corporation Limited (Singapore),
  • HCA Holdings, Inc. (US)

Market Segmentation:

Ambulatory Services market has been segmented on the basis of product type which comprises of Hospital emergency departments (EDs), Primary care offices, Hospital-based outpatient departments (OPDs), physician private practices, Community Health Centers, Ambulatory surgery centers (ASCs), Urgent Care Centers, and Others.

Access Report Details @ https://www.marketresearchfuture.com/reports/ambulatory-services-market-2491

Regional Analysis:

Depending on geographic region, Ambulatory Services market is segmented into four key regions: Americas, Europe, Asia-Pacific, and Middle East & Africa. Considering the global scenario of the market, North America comprise largest market share in global Ambulatory Services market. Moreover the European market is also growing continuously. On the other hand, Asia-Pacific market is expected to grow at the significant rate in the Ambulatory Services market segment during the forecasted period. Rest of the World is likely to have a limited but steady growth in the market.

Browse Related Report

Wearable Sensors Market Information, by Types (Motion Sensors, Medical Based Sensors, Image sensors, Position Sensors, Pressure Sensors, Inertial Sensors and Others), by Application (Smart Wristwear, Smart Glasses, Smart Bodywears, Smart Footwear and Other Wearable Devices) by End User (Consumer, Healthcare, Enterprise and Industrial and Others) – Forecast to 2020

https://www.marketresearchfuture.com/reports/wearable-sensors-market

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact
Akash Anand,
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: akash.anand@marketresearchfuture.com

SOURCE Market Research Future

Related Links

https://www.marketresearchfuture.com

Read More
Corporate_video_building_788x335.jpg

Anika to Issue First-Quarter 2017 Financial Results and Business Highlights on Wednesday, May 3

Posted On April 20, 2017 By OrthoSpineNews In Financial /  

April 19, 2017

BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first-quarter 2017 financial results after the close of the market on Wednesday, May 3, 2017 and to hold a conference call the next day, Thursday, May 4, 2017, at 9:00 a.m. ET to discuss its financial results, business highlights, and outlook.

The conference call can be accessed by dialing 1-855-468-0611 (toll-free domestic) or 1-484-756-4332 (international). A live audio webcast will be available in the “Investor Relations” section of Anika’s website, www.anikatherapeutics.com. An accompanying slide presentation also can be accessed via the Anika Therapeutics website. The call will be archived and accessible on the same website shortly after its conclusion.

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology. Anika’s orthopedic medicine portfolio includes ORTHOVISC®, MONOVISC®, and CINGAL®, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST®, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.

Contacts

For Investor Inquiries:
Anika Therapeutics, Inc.
Sylvia Cheung, 781-457-9000
Chief Financial Officer
or
For Media Inquiries:
Pure Communications, Inc.
Katie Engleman, 910-509-3977

Read More
mazor-robotics-7x4.jpg

Mazor Robotics to Report First Quarter Financial Results on May 10, 2017

Posted On April 20, 2017 By OrthoSpineNews In Financial /  

April 20, 2017

CAESAREA, Israel–(BUSINESS WIRE)–Mazor Robotics Ltd. (TASE:MZOR; NASDAQGM:MZOR), a pioneer and a leader in the field of surgical guidance systems, announced today that it will report financial results for the first quarter ended March 31, 2017, before the U.S. markets open on Wednesday, May 10, 2017.

The company will host a conference call to discuss these results on Wednesday, May 10, 2017, at 8:30 AM ET (3:30 PM IST). Investors within the United States interested in participating are invited to call 888-298-3457. Participants in Israel can use the toll-free dial-in number 1 80 924 5906. All other international participants can use the dial-in number 719-457-2689. For all callers, refer to Conference ID 8737181.

A replay of the event will be available for two weeks following the conclusion of the call. To access the replay, callers in the United States can call 1-866-375-1919 and reference the Replay Access Code: 8737181. All international callers can dial +1 719-457-0820, using the same Replay Access Code. To access the webcast, please visit www.mazorrobotics.com and select ‘Investor Relations.’

About Mazor

Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary technologies and products aimed at redefining the gold standard of quality care. Mazor Robotics Guidance Systems enable surgeons to conduct spine and brain procedures in an accurate and secure manner. For more information, please visit www.MazorRobotics.com.

Contacts

U.S. Contacts:
EVC Group
Investors
Michael Polyviou, 212-850-6020
mpolyviou@evcgroup.com
Doug Sherk, 415-652-9100
dsherk@evcgroup.com
or
Financial Media Contact
Tom Gibson, 201-476-0322
tom@tomgibsoncommunications.com

Read More
stem-cell-spinal_cord.jpg

InVivo Therapeutics Announces Oral Presentations at the 2017 American Spinal Injury Association Annual Scientific Meeting

Posted On April 20, 2017 By OrthoSpineNews In Neuro, Sports Medicine /  

April 20, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company will be giving two oral presentations at the 2017 American Spinal Injury Association (ASIA) Annual Scientific Meeting to be held April 26-29, 2017 in Albuquerque, New Mexico. Alex Aimetti, Ph.D., Vice President, Medical Education and Scientific Support, will present a clinical trial update during the “Clinical Trials 360-degree” session sponsored by Spinal Cord Outcomes Partnership Endeavor (SCOPE) on Friday, April 28. Dr. Aimetti will also present an abstract entitled “Relationship of ASIA Impairment Scale (AIS) Grade to Post-injury Hospitalization Costs in Thoracic Spinal Cord Injury” during a general session on Saturday, April 29. The abstract is co-authored by Dr. Aimetti, Ellen Dukes, Ph.D., Steven Kirshblum, M.D., Sarah Qin, M.B.A., Rebecca Bornheimer, B.A., and Gerry Oster, Ph.D. In addition to the two oral presentations, the company will have an exhibit booth at the meeting.

Mark Perrin, Chairman and CEO, said, “The American Spinal Injury Association Annual Scientific Meeting will allow us to continue to strengthen and expand our relationships within the spinal cord injury research and care network, and we look forward to having a significant presence at this meeting. We are also pleased to be providing an update on our clinical program, especially given our significant progress throughout the start of this year.”

About the Neuro-Spinal Scaffold™ Implant

Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in The INSPIRE Study for the treatment of patients with acute, complete (AIS A), thoracic traumatic spinal cord injury and a pilot study for acute, complete (AIS A), cervical (C5-T1) traumatic spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffoldreceived the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect,” “designed to,” “potentially,” and similar expressions, and include statements regarding the safety and effectiveness of the Neuro-Spinal Scaffold and the progress of the clinical program. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the company’s ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board process; the company’s ability to commercialize its products; the company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the company’s products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the company’s Annual Report on Form 10-K for the year ended December 31, 2016, and its other filings with the SEC, including the company’s Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these forward-looking statements.

Contacts

InVivo Therapeutics Holdings Corp.
Heather Hamel, 617-863-5530
Investor Relations
Investor-relations@invivotherapeutics.com

Read More
rti-surgical-corporate-photos-45.jpg

RTI Surgical® Schedules 2017 First Quarter Earnings Call for April 27, 2017

Posted On April 20, 2017 By OrthoSpineNews In Financial /  

April 20, 2017

ALACHUA, Fla.–(BUSINESS WIRE)–RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, announced today that it plans to release financial results from the first quarter 2017 on Thursday, April 27, 2017, prior to the market open.

RTI will host a conference call and simultaneous audio webcast to discuss first quarter results at 8:30 a.m. ET the same day. The conference call can be accessed by dialing (877) 383-7419 (U.S.) or (760) 666-3754 (International). The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A replay of the conference call will be available on RTI’s website for one month following the call.

About RTI Surgical Inc.

RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

Contacts

RTI Surgical Inc.
Robert Jordheim
Chief Financial Officer
rjordheim@rtix.com
or
Roxane Wergin, 386-418-8888
Director, Corporate Communications
rwergin@rtix.com

Read More
iFactor_iFactor_WEB.jpg

Oxford Finance Provides $20 Million Senior Debt Facility to Cerapedics Inc.

Posted On April 19, 2017 By OrthoSpineNews In Financial, Top Stories /  

ALEXANDRIA, Va. and WESTMINSTER, Colo., April 19, 2017 /PRNewswire/ — Oxford Finance LLC (“Oxford”), an industry-leading specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced the closing of a $20 million senior secured term loan with Cerapedics Inc. (“Cerapedics”) a privately-held orthobiologics company engaged in the development and commercialization of bone graft substitute products for the treatment of orthopedic injuries.

Cerapedics’ lead product, i-FACTOR Peptide Enhanced Bone Graft, is the only biologic bone graft that uses a unique small peptide attachment factor (P-15) bound to anorganic bone mineral (ABM). The i-FACTOR is the first and only FDA-approved product for Anterior Cervical Discectomy and Fusion (ACDF) and is the first device to demonstrate superiority versus autograft.

Loan proceeds are being used to support the ongoing commercialization of i-FACTOR’s use in cervical spine procedures and help fund a FDA study on its application in Transforaminal Lumbar Interbody Fusion (TLIF.)

“We are encouraged by the strength of i-FACTOR’s clinical safety and efficacy data,” said Christopher A. Herr, senior managing director at Oxford Finance. “Oxford is pleased to provide capital to help Cerapedics continue to enhance the science of bone repair.”

“We are pleased to be working with a strong partner in Oxford Finance in executing on our key growth initiatives,” said Glen Kashuba, chief executive officer of Cerapedics.

About Oxford Finance LLC

Oxford Finance is a specialty finance firm providing senior secured loans to public and private life sciences and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. Oxford has originated over $4 billion in loans, with credit facilities ranging from $5 million to $100 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in San Diego, California; Palo Alto, California; Salt Lake City, Utah and the greater Boston area. For more information, visit oxfordfinance.com.

About Cerapedics Inc.

Cerapedics is an orthobiologics company focused on developing and commercializing its proprietary synthetic small peptide (P-15) technology platform. i-FACTOR Peptide Enhanced Bone Graft is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. This novel mechanism of action is designed to support safer and more predictable bone formation compared to commercially available bone growth factors. More information can be found at cerapedics.com.

Media Contacts:

Amanda Stern 

Troy Wilford

Oxford Finance LLC 

Cerapedics Inc.

Tel: (888)471-0174 

Tel: (484)247-8054

astern@oxfordfinance.com 

twilford@cerapedics.com

 

SOURCE Oxford Finance Corporation

Related Links

http://www.oxfordfinance.com

Read More